Literature DB >> 8600955

Petrous bone extension of middle-ear acquired cholesteatoma.

Y Robert1, F Dubrulle, S Carcasset, C Hennequin, L Gaillandre, F M Vanecloo, L Lemaitre.   

Abstract

PURPOSE: To describe CT and MR features of extension to the petrous bone, which is a rare complication of acquired cholesteatoma (AC).
MATERIAL AND METHODS: Postcontrast CT was performed in 4 patients, in axial (n=4) and coronal planes (n=2). The section thickness was 1.2 or 2.5 mm. MR was performed in 3 cases, using T1- and T2-weighted images (n=3) and postcontrast T1-weighted images (n=2).
RESULTS: CT demonstrated a well-outlined lesion involving the petrous bone (n=4). Density could be assessed in 3 cases, showing a hypodense unenhanced mass. Lateral (n=1), superior (n=2), and posterior (n=2) semicircular canals were affected in 3 patients. AC extended to the vestibula, cochlea, and internal acoustic meatus (IAM) in 3 patients. Two ACs extended to the level of IAM, whereas 2 extended further, to the petrous apex. In one case the sphenoid sinus was affected. On MR imaging the lesion was hypointense relative to brain on T1-weighted images and hyperintense on T2-weighted images. MR imaging helped to delineate the lesion and to distinguish it from other cystic lesions of the petrous bone.
CONCLUSION: CT and MR offer accurate preoperative assessment of the extension of cholesteatoma, which helps to choose the surgical approach.

Entities:  

Mesh:

Year:  1996        PMID: 8600955     DOI: 10.1177/02841851960371P134

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.990


  2 in total

1.  Role of High Resolution Computed Tomography of Mastoids in Planning Surgery for Chronic Suppurative Otitis Media.

Authors:  Pritam Chatterjee; Swagata Khanna; Ramen Talukdar
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2015-07-01

2.  Middle ear cholesteatoma: characteristic CT findings in 64 patients.

Authors:  Joselito L Gaurano; Ismail A Joharjy
Journal:  Ann Saudi Med       Date:  2004 Nov-Dec       Impact factor: 1.526

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.